These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 17376486

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing.
    Blumhardt LD.
    Int J Clin Pract Suppl; 2002 Sep; (131):9-16. PubMed ID: 12564807
    [Abstract] [Full Text] [Related]

  • 7. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP.
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interferon after 10 years in patients with multiple sclerosis.
    Pozzilli C, Prosperini L, Sbardella E, Paolillo A.
    Neurol Sci; 2006 Sep; 27 Suppl 5():S369-72. PubMed ID: 16998723
    [Abstract] [Full Text] [Related]

  • 10. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, Feichter J, Patrick K, Munschauer F, Bakshi R, Ramanathan M.
    J Neuroimmunol; 2008 Dec 15; 205(1-2):113-25. PubMed ID: 18950872
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.
    Cunningham A, Gottberg K, von Koch L, Hillert J.
    Acta Neurol Scand; 2010 Mar 15; 121(3):154-60. PubMed ID: 20055771
    [Abstract] [Full Text] [Related]

  • 14. Interferon-beta1b for multiple sclerosis.
    Burks J.
    Expert Rev Neurother; 2005 Mar 15; 5(2):153-64. PubMed ID: 15853486
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP, Italian Multiple Sclerosis Database Network (MSDN) Group.
    Ann Neurol; 2009 Oct 15; 66(4):513-20. PubMed ID: 19847899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.